Molecular radionuclide imaging of pancreatic neoplasms

Ananya Panda, Ishan Garg, Geoffrey B Johnson, Mark Truty, Thorvardur R Halfdanarson, Ajit Goenka

Research output: Contribution to journalReview article

Abstract

Pancreatic neoplasms have high morbidity and dismal prognosis. Substantial progress in translational research and advances in scanner technology have resulted in rapid integration of molecular radionuclide imaging of pancreatic neoplasms into mainstream clinical practice. Metabolic imaging with 18F-FDG PET has extensive utility in the staging, assessment of treatment response, and follow-up of pancreatic ductal adenocarcinoma. Integrated PET/MRI has the potential to further expand this utility and lead to innovative applications. Somatostatin receptor PET imaging has had a profound effect on the evaluation and management of pancreatic neuroendocrine tumours. Peptide receptor radionuclide therapy is a new frontier in personalised medicine because it customises treatment to the unique biological features of a patient and the molecular signature of the patient's tumour. Further investigation is needed to optimise use of advanced molecular imaging techniques and novel radiotracers to achieve better outcomes for patients with pancreatic neoplasms.

Original languageEnglish (US)
Pages (from-to)559-570
Number of pages12
JournalThe Lancet Gastroenterology and Hepatology
Volume4
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Molecular Imaging
Pancreatic Neoplasms
Radionuclide Imaging
Somatostatin Receptors
Precision Medicine
Translational Medical Research
Peptide Receptors
Neuroendocrine Tumors
Fluorodeoxyglucose F18
Radioisotopes
Adenocarcinoma
Therapeutics
Technology
Morbidity
Neoplasms

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Molecular radionuclide imaging of pancreatic neoplasms. / Panda, Ananya; Garg, Ishan; Johnson, Geoffrey B; Truty, Mark; Halfdanarson, Thorvardur R; Goenka, Ajit.

In: The Lancet Gastroenterology and Hepatology, Vol. 4, No. 7, 01.07.2019, p. 559-570.

Research output: Contribution to journalReview article

Panda, Ananya ; Garg, Ishan ; Johnson, Geoffrey B ; Truty, Mark ; Halfdanarson, Thorvardur R ; Goenka, Ajit. / Molecular radionuclide imaging of pancreatic neoplasms. In: The Lancet Gastroenterology and Hepatology. 2019 ; Vol. 4, No. 7. pp. 559-570.
@article{1e1a73c2dcea4422b9f1fa3c414d6392,
title = "Molecular radionuclide imaging of pancreatic neoplasms",
abstract = "Pancreatic neoplasms have high morbidity and dismal prognosis. Substantial progress in translational research and advances in scanner technology have resulted in rapid integration of molecular radionuclide imaging of pancreatic neoplasms into mainstream clinical practice. Metabolic imaging with 18F-FDG PET has extensive utility in the staging, assessment of treatment response, and follow-up of pancreatic ductal adenocarcinoma. Integrated PET/MRI has the potential to further expand this utility and lead to innovative applications. Somatostatin receptor PET imaging has had a profound effect on the evaluation and management of pancreatic neuroendocrine tumours. Peptide receptor radionuclide therapy is a new frontier in personalised medicine because it customises treatment to the unique biological features of a patient and the molecular signature of the patient's tumour. Further investigation is needed to optimise use of advanced molecular imaging techniques and novel radiotracers to achieve better outcomes for patients with pancreatic neoplasms.",
author = "Ananya Panda and Ishan Garg and Johnson, {Geoffrey B} and Mark Truty and Halfdanarson, {Thorvardur R} and Ajit Goenka",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/S2468-1253(19)30081-0",
language = "English (US)",
volume = "4",
pages = "559--570",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Molecular radionuclide imaging of pancreatic neoplasms

AU - Panda, Ananya

AU - Garg, Ishan

AU - Johnson, Geoffrey B

AU - Truty, Mark

AU - Halfdanarson, Thorvardur R

AU - Goenka, Ajit

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Pancreatic neoplasms have high morbidity and dismal prognosis. Substantial progress in translational research and advances in scanner technology have resulted in rapid integration of molecular radionuclide imaging of pancreatic neoplasms into mainstream clinical practice. Metabolic imaging with 18F-FDG PET has extensive utility in the staging, assessment of treatment response, and follow-up of pancreatic ductal adenocarcinoma. Integrated PET/MRI has the potential to further expand this utility and lead to innovative applications. Somatostatin receptor PET imaging has had a profound effect on the evaluation and management of pancreatic neuroendocrine tumours. Peptide receptor radionuclide therapy is a new frontier in personalised medicine because it customises treatment to the unique biological features of a patient and the molecular signature of the patient's tumour. Further investigation is needed to optimise use of advanced molecular imaging techniques and novel radiotracers to achieve better outcomes for patients with pancreatic neoplasms.

AB - Pancreatic neoplasms have high morbidity and dismal prognosis. Substantial progress in translational research and advances in scanner technology have resulted in rapid integration of molecular radionuclide imaging of pancreatic neoplasms into mainstream clinical practice. Metabolic imaging with 18F-FDG PET has extensive utility in the staging, assessment of treatment response, and follow-up of pancreatic ductal adenocarcinoma. Integrated PET/MRI has the potential to further expand this utility and lead to innovative applications. Somatostatin receptor PET imaging has had a profound effect on the evaluation and management of pancreatic neuroendocrine tumours. Peptide receptor radionuclide therapy is a new frontier in personalised medicine because it customises treatment to the unique biological features of a patient and the molecular signature of the patient's tumour. Further investigation is needed to optimise use of advanced molecular imaging techniques and novel radiotracers to achieve better outcomes for patients with pancreatic neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=85066396342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066396342&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(19)30081-0

DO - 10.1016/S2468-1253(19)30081-0

M3 - Review article

C2 - 31169124

AN - SCOPUS:85066396342

VL - 4

SP - 559

EP - 570

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 7

ER -